Literature DB >> 22878444

Vitreous levels of somatostatin in patients with chronic uveitic macular oedema.

A Fonollosa1, E Coronado, R Catalan, M Gutierrez, C Macia, M A Zapata, N Martinez-Alday, R Simo, J Garcia-Arumi.   

Abstract

PURPOSE: Intravitreal somatostatin (SST) levels are decreased in patients with diabetic macular oedema. This deficit may be involved in the pathogenesis of this condition. The aim of the present study was to determine SST concentration in the vitreous fluid of patients with chronic uveitic macular oedema (CUMO) and quiescent intraocular inflammation.
METHODS: Plasma and vitreous fluid samples were obtained during vitrectomy from 11 eyes of patients with CUMO and from 42 eyes of control subjects (idiopathic epiretinal membrane, macular hole). SST concentration was measured by radioimmunoassay. STATISTICS: χ(2)-square test, Mann-Whitney U-test, Wilcoxon test, Spearman's rank correlation coefficient, and multivariant linear regression models.
RESULTS: Plasma SST concentrations were similar in uveitic patients and controls (28.25 pg/ml (21.3-31) vs 28.7 pg/ml (22-29.5); P=0.869). A higher vitreous concentration of proteins was found in uveitic patients (1.59±0.38 mg/ml vs 0.73±0.32 mg/ml, P<0.0001). Vitreous SST was markedly lower in uveitic patients, both in absolute terms and after adjusting for total intravitreous protein concentration (39.37 pg/ml (6.16-172) vs 486.73 pg/ml (4.7-1833), P<0.0001; 33.1 pg/mg (3.9-215.74) vs 629.75 pg/mg (6.91-2024), P<0.0001). No correlations were found between plasma and vitreous concentration of SST in either group (ρ=0.191, P=0.57 and ρ=0.49, P=0.66). There were no correlations between vitreous SST concentration and visual acuity or macular thickness in uveitic patients (ρ=0.302, P=0.31 and ρ=0.45, P=0.13).
CONCLUSIONS: Intravitreous SST is decreased in patients with CUMO and quiescent intraocular inflammation. The deficit of SST may have a role in the pathogenesis of this condition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878444      PMCID: PMC3470056          DOI: 10.1038/eye.2012.161

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  26 in total

Review 1.  Somatostatin and somatostatin receptors in retinal diseases.

Authors:  P M van Hagen; G S Baarsma; C M Mooy; E M Ercoskan; E ter Averst; L J Hofland; S W Lamberts; R W Kuijpers
Journal:  Eur J Endocrinol       Date:  2000-10       Impact factor: 6.664

2.  International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease.

Authors:  E Bloch-Michel; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

3.  Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.

Authors:  R B Nussenblatt; A G Palestine; C C Chan; F Roberge
Journal:  Ophthalmology       Date:  1985-04       Impact factor: 12.079

4.  Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina.

Authors:  Massimo Dal Monte; Cristina Petrucci; Andrea Cozzi; Jeremy P Allen; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-14       Impact factor: 3.000

5.  Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema.

Authors:  H F Fine; J Baffi; G F Reed; K G Csaky; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2001-11       Impact factor: 5.258

6.  Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells.

Authors:  Jeffrey W Sall; Dino D Klisovic; M Sue O'Dorisio; Steven E Katz
Journal:  Exp Eye Res       Date:  2004-10       Impact factor: 3.467

7.  Human RPE cell apoptosis induced by activated monocytes is mediated by caspase-3 activation.

Authors:  Susan G Elner; Ayako Yoshida; Zong-Mei Bian; Andrei L Kindezelskii; Howard R Petty; Victor M Elner
Journal:  Trans Am Ophthalmol Soc       Date:  2003

8.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

9.  Somatostatin is an immunosuppressive factor in aqueous humor.

Authors:  Andrew W Taylor; David G Yee
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-06       Impact factor: 4.799

10.  A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema.

Authors:  Syed Mahmood Ali Shah; Quan Dong Nguyen; Hafsa Syyida Mir; Antonio Polito; Gulnar Hafiz; Sinan Tatlipinar; Diana V Do; Susan Vitale; Julia A Haller
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

View more
  1 in total

Review 1.  Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy.

Authors:  Maria Grazia Rossino; Massimo Dal Monte; Giovanni Casini
Journal:  Front Neurosci       Date:  2019-11-08       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.